Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.
Mehul Gupta, Daniel Yick Chin Heng(University of Calgary), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Connor Wells(Queen Mary University of London), Ravindran Kanesvaran(University of Ioannina), Vishal Navani(Hunter Medical Research Institute), Sumanta K. Pal(City of Hope), Renée Maria Saliby(Yale University), Toni K. Choueiri(Harvard University), Rana R. McKay(University of California San Diego), Meredith M. Regan(Dana-Farber Cancer Institute), Jae‐Lyun Lee(Ulsan College), Kosuke Takemura(Japanese Foundation For Cancer Research), Wanling Xie(Dana-Farber Cancer Institute), Thomas Powles(Queen Mary University of London), Megan Crumbaker(Garvan Institute of Medical Research), Christian Kollmannsberger(BC Cancer Agency), Takeshi Yuasa(Japanese Foundation For Cancer Research), Frede Donskov(Aarhus University Hospital), Naveen S. Basappa
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k